cytarabine has been researched along with quinoxalines in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanc, EM; Guiramand, J; Jallageas, M; Recasens, M | 1 |
| Bruserud, O; Hatfield, KJ; Kalland, KH; Kittang, AO; Oyan, AM; Reikvam, H | 1 |
2 other study(ies) available for cytarabine and quinoxalines
| Article | Year |
|---|---|
Potentiation of glutamatergic agonist-induced inositol phosphate formation by basic fibroblast growth factor is related to developmental features in hippocampal cultures: neuronal survival and glial cell proliferation.
Topics: Animals; Antimetabolites, Antineoplastic; Benzoates; Cell Division; Cell Survival; Cells, Cultured; Cellular Senescence; Cycloleucine; Cytarabine; Epidermal Growth Factor; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Fetus; Fibroblast Growth Factor 2; Glutamic Acid; Glycine; Hippocampus; Inositol Phosphates; Neuroglia; Neurons; Neuroprotective Agents; Quinoxalines; Quisqualic Acid; Rats; Receptors, AMPA; Receptors, Kainic Acid; Type C Phospholipases | 1999 |
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiopoietin-2; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Diterpenes; Endothelial Cells; Female; Humans; Imidazoles; Leukemia, Myeloid; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Quinoxalines; Receptor, TIE-2; Recombinant Proteins; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2010 |